Confluent Medical Technologies Names Matthew K. Eckl as Chief Financial Officer

Confluent Medical Technologies Names Matthew K. Eckl as Chief Financial Officer

Confluent Medical Technologies, Inc. announced that Matthew K. Eckl, has been appointed as Chief Financial Officer (“CFO”) for the company, effective October 17, 2022.


“We are thrilled to welcome Matt to Confluent,” said Dean Schauer, Confluent’s Chief Executive Officer. “Matt has exceptional experience in finance and financial operations as well as leadership across a variety of design and manufacturing organizations. As Confluent continues its significant growth, the addition of Matt to our company will further enhance the strength of our industry-leading team.”


As CFO, Mr. Eckl’s responsibilities will span global financial strategy and financial operations and he will lead Confluent’s Accounting, Financial Planning and Analysis, Legal, and Information Technology teams.


Mr. Eckl joins Confluent from CECO Environmental (NASDAQ: CECE), where he served as CFO for five years based in Dallas, TX. Prior to that, Mr. Eckl served as Vice President of Finance for Energy Group and Global Aftermarket division of Gardner Denver in Houston, TX. Before Gardner Denver, he served in several financial roles at GE. Mr. Eckl has a Bachelor of Science in Management Information Systems from Pennsylvania State University.


Commenting on his appointment, Mr. Eckl said: “I am excited to join one of the medical device industry’s most trusted partners. Confluent’s ability to deliver world-class medical devices through its innovative material science, engineering, and manufacturing capabilities is truly remarkable. Confluent’s demonstrated focus on its mission, values, and culture was a key determinant in my decision to join its highly experienced management team.”


Source: Confluent Medical Technologies

«« Smartphones Predict Mortality Risk


Worsening Heart Disease Because of Global Warming »»

Published on : Mon, 17 Oct 2022



Related Articles

Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with... Read more

Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation... Read more

OpSens Inc. , a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology,... Read more

Confluent Medical Technologies,Matthew K. Eckl,Chief Financial Officer,CFO Confluent Medical Technologies, Inc. announced that Matthew K. Eckl, has been appointed as Chief Financial Officer (“CFO”) for the company, effective October 17, 2022.

No comment


Please login to leave a comment...